AIMIA DECLARES PREFERRED SHARE DIVIDENDS
TORONTO, Aug. 11, 2023 /CNW/ - Aimia (TSX: AIM) announced today that the Board of Directors has declared quarterly dividends on each series of its preferred shares:
- a quarterly dividend in the amount of $0.300125 per Cumulative Rate Reset Preferred Share, Series 1
- a quarterly dividend of $0.375688 per Cumulative Rate Reset Preferred Share, Series 3
In each case, dividends are payable on September 29, 2023, to the holders of record at the close of business on September 15, 2023.
Dividends paid by Aimia to Canadian residents on its preferred shares are "eligible dividends" for the purpose of the Income Tax Act (Canada) and any similar applicable provincial legislation.
About AimiaAimia Inc. (TSX: AIM) is a holding company that makes long-term investments in private and public businesses through controlling or minority stakes. We target companies with durable economic advantages evidenced by a track record of substantial free cash flow generation over complete business cycles, strong growth prospects, and guided by strong, experienced management teams. Headquartered in Toronto, Canada, Aimia is positioned to invest in any sector, wherever a suitable opportunity can be identified worldwide. In addition, we seek investments that may efficiently utilize the Company's operating and capital loss carry-forwards to further enhance stakeholder value.
For more information about Aimia, visit www.aimia.com.
SOURCE Aimia Inc.
Ausgewählte Hebelprodukte auf Hemispherx Biopharma
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Hemispherx Biopharma
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Hemispherx Biopharma Aktie News
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Hemispherx Biopharma Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Hemispherx Biopharma nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
Keine Analysen gefunden.